Syros pharmaceuticals, inc. (SYRS)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Operating activities
Net loss

-17,226

-19,729

-19,793

-19,455

-16,461

-18,032

-15,737

-14,047

-14,463

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-13,825

-13,368

-11,515

-

-14,169

-12,021

-10,588

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization

678

835

582

587

517

432

408

376

388

390

391

381

365

338

315

316

304

Amortization of financing right-of-use asset

65

63

61

62

15

-

-

-

-

-

-

-

-

-

-

-

-

Gain on disposal of fixed assets and modification of lease

-

-

-

-

-1

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

2,459

3,216

2,389

2,355

1,879

1,633

1,537

1,744

1,696

1,271

1,108

1,156

884

730

1,694

1,148

662

Net amortization of premiums and discounts on marketable securities

49

198

209

246

296

308

219

46

69

75

40

-6

-7

-

-

-

-

Amortization of debit-discount and accretion of deferred debt costs

40

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-358

-44

232

753

-158

-258

-910

1,149

519

-109

-643

209

412

-339

-650

945

552

Accounts receivable

-20,000

-

-

-

-

-

-

-

-

0

0

-551

-316

-

-

-

-

Contract assets

1,477

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other long-term assets

286

-

-6

-6

14

-11

29

19

-3

-5

2

386

-18

-

-

-

-

Accounts payable

-1,060

1,401

1,643

-941

-610

519

1,379

-448

-562

436

492

-1,007

220

-1,830

2,849

-509

-914

Accrued expenses

-3,357

-974

2,012

352

-4,966

2,662

2,226

-28

-669

2,684

1,779

1,144

-2,074

2,216

2

927

540

Deferred revenue

-902

19,650

-558

-462

-454

-893

-413

-374

11,882

0

0

0

-550

-

-

-

-

Proceeds for tenant improvement incentive from landlord

586

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease asset and liabilities

-417

1,797

-2,862

-396

96

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent and lease incentive

-

-

-

-

-

-94

-87

-87

-87

-85

-78

-78

-79

-75

-69

-70

-70

Net cash provided by (used in) operating activities

246

-10,603

-11,224

-18,099

-20,327

-13,812

-10,025

-14,078

-2,400

-10,567

-9,532

-11,810

-12,820

-

-

-

-

Investing activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10,618

Purchases of property and equipment

1,797

8,157

2,570

1,320

591

195

1,021

16

152

67

46

312

396

314

181

302

1,525

Purchases of marketable securities

-

0

74,570

-2

33,638

24,768

69,514

0

2,486

-

-

-

-

-

-

-

-

Maturities of marketable securities

45,000

25,000

20,000

34,000

30,000

45,000

10,000

17,500

15,000

0

12,000

12,501

2,499

-

-

-

-

Net cash provided by (used in) investing activities

43,203

16,953

-57,140

32,682

-4,229

20,037

-60,526

17,484

12,362

-69

-27,819

10,194

2,103

-

-

-

-

Financing activities
Payments on financing and capital lease obligations

58

56

55

54

40

2

2

2

44

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,525

Payments on capital lease obligations

-

-

-

-

-

-

-

-

-

-

42

42

41

40

40

38

17

Proceeds from issuance of common stock through employee benefit plans

100

160

44

4

3

139

0

245

242

881

200

549

169

-

-

-

-

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2

39,811

Proceeds from issuance of common stock through at-the-market sales agreement, net of issuance costs

11,937

-

-

-

-

-

-

-

51,969

-

-

-

-

-

-

-

-

Proceeds from term loan, net of issuance costs

19,714

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of offering costs

-

-

-

-

78

-

-

-

-

-

-

-

-

-

-

885

1,427

Net cash provided by (used in) financing activities

31,693

1,089

-12

65,028

-115

137

327

16,453

52,167

692

-31

33,148

128

-

-

-

-

Increase (decrease) in cash, cash equivalents and restricted cash

75,142

7,439

-68,376

79,611

-24,671

6,362

-70,224

19,859

62,129

-9,944

-37,382

31,532

-10,589

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

38,367

Increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

43,378

-12,017

26,224

Supplemental disclosure of cash flow information:
Cash paid for interest

231

20

21

23

8

1

0

0

1

1

2

3

3

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5

Non-cash investing and financing activities:
Property and equipment received but unpaid as of period end

991

-3,208

3,729

814

230

191

30

41

6

134

-37

32

14

273

-36

-84

196

Assets acquired under financing lease

-

-

-

-

996

-

-

-

-

-

-

-

-

-

-

-

-

Deferred financing costs incurred but unpaid as of period end

10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering costs incurred but unpaid as of period end

41

-27

47

-126

129

-

-

-65

67

-47

20

15

25

-

-

390

235